Wat is de prijs voor Paion AG (PA8)

Het prijs van Paion AG (PA8) is $0.42701586

Wat is de marktkapitalisatie voor Paion AG (PA8)

Marktkapitalisatie voorPaion AG (PA8) is $3.21M

Paion AG (PA8) K/O-verhouding

Paion AG is a specialized pharmaceutical firm engaged in the global development and commercialization of medicines for hospital settings, specifically addressing needs in sedation, anesthesia, and critical care. Its primary compound, Remimazolam, is an ultra-short-acting intravenous benzodiazepine designed as a sedative/anesthetic, currently progressing through clinical trials for applications in procedural sedation, general anesthesia, and intensive care unit sedation. The company's pipeline also includes Angiotensin II, a vasoconstrictor for treating severe low blood pressure in adults experiencing septic or other forms of distributive shock, and Eravacycline, a new fluorocycline antibiotic targeting complex intra-abdominal infections in adults. Paion AG collaborates with various partners through licensing and strategic agreements, including Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Established in 2000, Paion AG operates from Aachen, Germany.

Jaar	P/S-ratio	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

P/S-ratio

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	P/S-ratio	Verschil in P/S-ratio	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	7.73	-	IN

Bedrijf

P/S-ratio

Verschil in P/S-ratio

Land